BlackRock Institutional Trust’s Akebia Therapeutics AKBA Stock Holding History

BlackRock Institutional Trust’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8.29M	Buy	796,132 +19,264	+2%	+$166K	﹤0.01%	2511
2016 Q3	$7.03M	Buy	776,868 +1,833	+0.2%	+$15.6K	﹤0.01%	2548
2016 Q2	$5.8M	Buy	775,035 +5,020	+0.7%	+$43.8K	﹤0.01%	2607
2016 Q1	$6.94M	Buy	770,015 +212,846	+38%	+$1.73M	﹤0.01%	2499
2015 Q4	$7.2M	Buy	557,169 +10,853	+2%	+$111K	﹤0.01%	2522
2015 Q3	$5.28M	Buy	546,316 +380,520	+230%	+$3.49M	﹤0.01%	2685
2015 Q2	$1.71M	Buy	165,796 +92,042	+125%	+$785K	﹤0.01%	3177
2015 Q1	$819K	Sell	73,754 -805	-1%	-$8.57K	﹤0.01%	3397
2014 Q4	$868K	Buy	74,559 +516	+0.7%	+$7.4K	﹤0.01%	3385
2014 Q3	$1.64M	Sell	74,043 -8,466	-10%	-$194K	﹤0.01%	3166
2014 Q2	$2.29M	Buy	+82,509	New	+$1.99M	﹤0.01%	3130

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock Institutional Trust's AKBA Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Akebia Therapeutics (AKBA) stake by 2.5% in Q4 2016, buying an estimated $166K and bringing the position to 796,132 shares worth $8.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

BlackRock Institutional Trust first reported a position in AKBA in Q2 2014 and has held it in 11 quarters since. 94 funds tracked by Wall St. Rank hold AKBA as of Q4 2016.

BlackRock Institutional Trust held 796,132 shares of Akebia Therapeutics worth $8.29M as of Q4 2016.
BlackRock Institutional Trust bought 19,264 Akebia Therapeutics shares in Q4 2016, an estimated $166K.
Akebia Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2511 holding.
BlackRock Institutional Trust first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 11 quarters since.
94 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.